FDA Approves Groundbreaking iDose ® TR for Glaucoma Treatment Following Successful Clinical Trials Conducted by Parkhurst NuVision and Glaukos
Parkhurst NuVision, a leading ophthalmic clinic and Glaukos have reached a significant milestone with the U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for iDose® TR (travoprost intracameral implant) 75 mcg. This pioneering prostaglandin analog...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI FDA Source Type: news
More News: Clinical Trials | Food and Drug Administration (FDA) | Glaucoma | New Drug Applications | Opthalmology | Pharmaceuticals | Travatan